Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04758611 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The ETCHES I Study (Endovascular Treatment of Communicating Hydrocephalus With an Endovascular Shunt)

Study acronym: ETCHES I
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruitingv11 Show 4 more changesShow less
    • Enrollment target: estimated 30 to confirmed 20
    • Primary completion date changed from estimate of Dec 1, 2025 to Jan 7, 2026
    • Study completion date: Dec 1, 2027 to Jan 7, 2028
    • Site details revised
  2. Primary completion date: Mar 1, 2025 to Dec 1, 2025
    • Study completion date: Mar 1, 2027 to Dec 1, 2027
    • Publications: details revised at 1 of 3 entries
    v10
  3. Re-verified, no change to tracked fieldsv9
  4. Primary completion date: Dec 1, 2024 to Mar 1, 2025
    • Study completion date: Dec 1, 2026 to Mar 1, 2027
    • Publications: details revised at 1 of 3 entries
    v8
  5. Primary completion date: Dec 1, 2023 to Dec 1, 2024
    • Study completion date: Mar 1, 2024 to Dec 1, 2026
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: May 1, 2023 to Dec 1, 2023
    • Study completion date: Jun 1, 2023 to Mar 1, 2024
    v6
  2. Primary completion date: Dec 1, 2022 to May 1, 2023
    • Study completion date: Jan 1, 2023 to Jun 1, 2023
    v5
  3. Primary completion date: Jul 1, 2022 to Dec 1, 2022
    • Study completion date: Nov 1, 2023 to Jan 1, 2023
    v4
  4. Eligibility criteria expanded, about 17 words
    • Publications: 2 to 3
    • Study description shortened, about 4 words
    v3
  5. Primary completion date: Oct 1, 2021 to Jul 1, 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The eShunt™ System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.
Trial Details
NCT Number NCT04758611
Lead Sponsor CereVasc Inc
Collaborators: AlvaMed, Inc., Bioscience Consulting, Inc., Simplified Clinical Data Systems, LLC
Conditions
(from sponsor)		 Hydrocephalus, Communicating, Hydrocephalus
Related terms Hydrocephalus
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov